CN108315349A - The application process of circular rna circRNF13 - Google Patents

Abstract

The invention discloses the application processes of circular rna circRNF13.The preparation for being specifically overexpressed circRNF13 is preparing the application reduced on preparation of the Tca8113 cells to cis-platinum class drug resistance.It confirms to be overexpressed circRNF13 in Dendritic cell mdr cell by studying, can obviously reverse the drug resistance of Tca8113 cells.Therefore, circRNF13 is overexpressed preparation for reducing the drug resistance of Tca8113 cells, there is far-reaching clinical meaning and important popularizing application prospect.

Description

The application process of circular rna circRNF13

Technical field

The invention belongs to oncomolecularbiology fields, and in particular to the reagent of circRNF13 expression is promoted to prepare drop Low Tca8113 cells are to the application on cis-platinum class drug resistance preparation.

Background technology

The Human Genome Project and its subsequent DNA element encyclopedia plan (The Encyclopedia of DNA Elements Project, ENCODE) achievement in research shows that protein coding gene sequence only accounts for the 1- of human genomic sequence 3%, and the transcribed sequence of the overwhelming majority is non-coding RNA (non-coding RNA, ncRNA) in human genome.Non- volume Code RNA is although non-coding protein, due to wide participation genes within cells expression regulation, in field of biomedical research one Directly it is concerned.Study more is linear ncRNA molecules, from RNA sequence length can be divided into Microrna (microRNA, MiRNA, 19-23nt) and long-chain non-coding RNA (long non-coding RNA, lncRNAs,>200nt), they including Important function is played in the occurrence and development of a variety of mankind's common diseases including malignant tumour.Recently, a kind of completely new NcRNA molecules, circular rna (circular RNA, circRNA) is due to its unique configuration and the important biomolecule increasingly found Function is learned, the new forward position of biomedical sector and hot spot are had become.

CircRNA had once once been taken as the wrong product during genetic transcription post-processing.With the lines such as mRNA and lncRNA Property RNA process it is much like, the formation of circRNA is also to be given birth to when carrying out montage processing to RNA precursors by splicing complex At, only in this course, the loop-forming sequences of flank combine cyclization, subsequent splicing complex to carry out montage first, most Flanking sequence cuts off to form circRNA at last.Recently as new-generation sequencings technologies such as sequencing technologies especially RNA-seq Development, more and more circRNA by research by it has been found that simultaneously disclose part circRNA in numerous life It all plays an important role in activity.Additionally due to its unique structure causes circRNA insensitive to nuclease, in tumour CircRNA also has a clear superiority in terms of the development and application of marker, therefore very likely as a kind of important molecular marker The target spot of object and emerging drug development.But since this field has just emerged, most of circRNA is not yet found or there is no Research.

Squamous cell carcinoma of tongue (tongue squamous cell carcinoma, TSCC) is that the highest oral cavity of incidence is disliked Property tumour, Dendritic cell majority is squamous carcinoma, mostly occurs in lingual margin, is often ulcer type or leaching secondly for the tip of the tongue, back and root of the tongue etc. Profit type.General grade malignancy is higher, and growth is fast, and wellability is stronger, and ordinary wave and lingualis cause tongue limitation of movement, make to speak, feed And it swallows and difficulty occurs.The chemotherapy that operative treatment is aided with based on suitable platinum medicine is Dendritic cell clinically main treatment side Case.However, finding that the therapeutic effect of Dendritic cell patient is often not satisfactory in clinic, survival rate is only 55-65% within 5 years, studies carefully it Reason essentially consists in the remaining cancer cell of operation, and (for example to have invaded the circulating tumor being transferred in blood vessel or lymphatic vessel thin Born of the same parents) generally existing drug resistance, lead oncogenic recurrence and transfer, cause treatment failure.Therefore, Tca8113 cells are found out to chemotherapy The resistance mechanisms of drug screen new drug target, final to improve survival and life quality, are to be worth clinical section The important topic that the workers of grinding study.

In order to study circRNA Tca8113 cells in cis-platinum class Drug-resistant effect and mechanism, we use The circRNA genetic chip Arraystar Human Circular RNA Microarray V2.0 couple two of Agilent companies The expression of circRNAs in Tca8113 cells strain (Tca8113 and Cal27) before and after cisplatin treated is analyzed.I Find circRNF13 expression variation it is the most notable, prompt circRNF13 may be related to the cisplatin resistance of Dendritic cell, and Up to the present, the biological function of circRNF13 and mechanism of action have no any report.

Since genetic chip can only be based on circRNA ring-type splicing site upstream and downstream sequence design probes, pass through these spies Needle specificity captures circRNA, to detect the gene expression abundance of circRNA in cell or tissue；Pass through particularly for us CircRNA chips find circRNF13 for, by genetic chip provide technical data we can find its corresponding spy The total 60bp of needle, the last period is the sequence of 8 exon, 3 ' the end 30bp of RNF13 genes, and latter section is then RNF13 genes 2 5 ' end 30bp of exon, it is to be joined end to end to add by No. 2 of the precursor RNA of RNF13 genetic transcriptions and 8 exons to prompt it Work forms, but specifically RNF13 which exon processing generates (whether 2~8 exons are included entirely withinWhether Also include intron sequencesBecause some circRNA include just intron sequences) it does not know.Then, our design primers are simultaneously Pass through the PCR successful clones nested twice full length sequence of circRNF13, it was confirmed that circRNF13 is strictly by being located at dye The 2-8 extras of RNF13 genes (ring finger protein 13, NM_183381.2) on the regions colour solid 3q25.1 are aobvious Subring is spliced to form, overall length 716bp.

In order to further study the biological function of circRNF13, it is dry that we devise the small molecule for circRNF13 The expression that RNA (siRNA) sequence-specific has struck circRNF13 low is disturbed, while successfully constructing circRNF13 over-express vectors CircRNF13 is overexpressed in Tca8113 cells.MTT and flow cytometry detection confirm that up-regulation circRNF13 can be bright Aobvious to inhibit Tca8113 cells proliferation, mechanism is arresting cell cycle and inducing cell apoptosis, and strikes low circRNF13 and then obtain Opposite result.Further, we successfully obtain Dendritic cell chemotherapy resistance cell strain, in real time by Fiber differentiation The expression of circRNF13 in quantitative PCR detection cell, find expression of the circRNF13 in drug-resistant cell strain with it is former Beginning cell strain is lowered compared to significantly；And we are overexpressed circRNF13 in mdr cell, can obviously reverse Dendritic cell thin The drug-resistant phenotype of born of the same parents, and the expression of low circRNF13 is struck in initial cell strain, then Tca8113 cells can be significantly improved to suitable The tolerance of platinum.

Finally, we are had detected in Dendritic cell clinical sample by real-time fluorescence quantitative PCR and the method for in situ hybridization The expression of circRNF13 finds that circRNF13 expresses notable downward in Dendritic cell, and circRNF13 expresses low trouble Its life span of person is shorter than circRNF13 and expresses high patient, therefore can be used for tongue for the detection preparation of the lncRNA The auxiliary diagnosis and Index for diagnosis of squamous carcinoma.

Invention content

The object of the present invention is to provide the application processes of circular rna circRNF13.Specifically promote circRNF13 expression Reagent is preparing reduction Tca8113 cells to the application on cis-platinum class drug resistance preparation, the circular rna The sequence of circRNF13 such as SEQ NO:Shown in 1.

The reagent of circular rna circRNF13 expression that promotes is circRNF13 over-express vectors.

The building process of the circRNF13 over-express vectors is as follows：

(1) it according to the fundamentum of the Forming Mechanism of circRNA and eucaryote RNA montages, designs and is suitable for The loop-forming sequences of circRNA expression；According to the sequence information of commercial carrier pcDNA3.1, suitable multiple cloning sites are designed, To obtain completely realizing that the DNA sequence dna that circRNA is overexpressed is as follows：

GTGCTGGGATTACAGGTGTGAGCTACCACCCCCGGCCCACTTTTTCTTAAGCTTGGTACCGAGCTCGGATCCACATC GATTGGTGGAATTCTGCAGATATCCACCGCGGTGGCGGCCGCTCGAGTCTAGAGAAAAGAATTAGGCTCGGCACGGT AGCTCACACCTGTAATCCCAGCA, intermediate underscore part are multiple cloning sites, and both ends are respectively upstream and downstream loop-forming sequences；

(2) above-mentioned synthesis is realized that NheI restriction enzyme site sequences are added in DNA sequence dna one end that circRNA is overexpressed, separately One end addition ApaI restriction enzyme site sequences obtain pcCirc by being built into pcDNA3.1 carriers after NheI and ApaI digestions Empty plasmid, sequencing confirm that plasmid is correct, sequence such as SEQ NO:Shown in 13；

(3) selection Cla I and Sac II restriction enzyme sites are used for digestion pcCirc empty plasmids, and by circRNF13 sequences It is inserted between the upstream and downstream loop-forming sequences of carrier.

The detailed process of step (3) is as follows：

1) using Tca8113 cells Tca8113cDNA as template, TaKaRa LA are utilizedEnzyme carries out PCR amplification overall length CircRNF13 sequences；CircRNF13 full length sequence amplimers are as follows：

Sense primer：5’-GTGATTTTACAACGAGAT-3’；

Downstream primer：5’-CTTTCTTGAATTTATGTA-3’；

In upstream and downstream, 5 ' ends of primer add restriction enzyme Cla I and Sac II recognition sites and protection alkali respectively After base, primer sequence is as follows：

Sense primer：5’-AGGAATCGATGTGATTTTACAACGAGAT-3 ', underscore part are that Cla I identify position Point；

Downstream primer：5’-ATGCCCGCGGCTTTCTTGAATTTATGTA-3 ', underscore part are that Sac II identify position Point；

2) PCR amplification, circRNF13 full length sequences, PCR reaction conditions are as follows：

PCR reaction steps

3) by through Cla I and Sac II double digestion rear electrophoresis, glue returns again after PCR product electrophoresis, glue recycling target fragment It receives；

4) pcCirc empty plasmids recycle target fragment through Cla I and Sac II double digestion rear electrophoresis glue；

5) with the connection of T4DNA ligases 3) and 4) step glue recovery product to get to the carrier matter for being overexpressed circRNF13 Grain；

6) by the eukaryon expression plasmid transformed competence colibacillus large intestine bar comprising circRNF13 full length sequences that 5) step obtains Bacterium, to expand plasmid.

We strike the expression (si-circRNF13) of low circRNF13 in original Tca8113 cells (NC) or in drug resistances After being overexpressed circRNF13 (OE-circRNF13) in cell (CR), with the cisplatin treated cell of same concentrations, then streaming is thin Born of the same parents' instrument detects Apoptosis situation, it is found that the expression for striking low circRNF13 can increase tolerance of the cell to cis-platinum (apoptosis subtracts It is few), and the drug resistance of mdr cell can be significantly reduced by being overexpressed circRNF13 then.Therefore, circRNF13 is overexpressed and is made Agent has far-reaching clinical meaning and important popularizing application prospect for reducing the drug resistance of Tca8113 cells.

Description of the drawings

Fig. 1：CircRNF13 is demonstrated by qRT-PCR, and significantly up-regulation (left side), sequencing result card are expressed after cisplatin treated That real qRT-PCR is detected is strictly circRNF13 (right side).Arrow represents splicing site, is 8 extras of RNF13 on the left of arrow Aobvious son 3 ' is held, and is 5 ' terminal sequences of 2 exon of RNF13 genes on the right side of arrow.

Fig. 2：It is sequenced by nesting PCR- twice, for the first time the successful clone full length sequence of circRNF13 molecules, it was demonstrated that CircRNA is by the 2-8 exon rings of the RNF13 gene transcripts NM_183381.2 on the regions chromosome 3q25.1 Change is spliced to form, overall length 716bp.

Fig. 3：Design simultaneously successfully build circRNF13 over-express vectors, using pcDNA3.1 carriers as basic framework, by Two sections of loop-forming sequences and restriction enzyme site is added in its CMV promoter downstream, and the 2-8 exons of RNF13 are passed through PCR, digestion are connected in carrier (left side), are then transfected into Tca8113 cells, are successfully overexpressed in Tca8113 cells CircRNF13 (right side).

Fig. 4：It is devised for circRNF13 ring-types splicing site (exon 8 and exon 2 junction) selectively targeted The siRNA sequence (left side) of the circular rna, is then transfected into Tca8113 cells, is successfully struck in Tca8113 cells low The expression (right side) of circRNF13.

Fig. 5：MTT proliferation experiments show compared with control group (NC), and being overexpressed circRNF13 (OE-circRNF13) can be with Inhibit the proliferation of Tca8113 cells, and the expression (si-circRNF13) for striking low circRNF13 can promote Tca8113 cells Proliferation.

Fig. 6：Flow cytometry analysis is found compared with control group (NC), is overexpressed circRNF13 (OE-circRNF13) Tca8113 cells G2/M phase distribution proportions obviously increase afterwards, show cell-cycle arrest in the G2/M phases, and strike low circRNF13's After expressing (si-circRNF13), the S phases, which are distributed, significantly increases, and shows that cell cycle progression accelerates.

Fig. 7：Flow cytometry analysis Apoptosis situation is found compared with control group (NC), is overexpressed circRNF13 (OE-circRNF13) Tca8113 cells apoptosis ratio obviously increases afterwards, in the case of normal culture, apoptosis of tumor cells ratio compared with Low, so striking the expression of low circRNF13, apoptotic cell ratio is in a slight decrease.

Fig. 8：CircRNF13 expression significantly reduces in chemotherapy resistance cell (CR) compared with control group (NC).

Fig. 9：The expression (si-circRNF13) of low circRNF13 is struck in original Tca8113 cells (NC) or in drug resistance After being overexpressed circRNF13 (OE-circRNF13) in cell (CR), with the cisplatin treated cell of same concentrations, then streaming is thin Born of the same parents' instrument detects Apoptosis situation, it is found that the expression for striking low circRNF13 can increase tolerance of the cell to cis-platinum (apoptosis subtracts It is few), and the drug resistance of mdr cell can be significantly reduced by being overexpressed circRNF13 then.

Figure 10：It is had detected by qRT-PCR in control tissue (N) by 28 pairs of fresh Dendritic cell biopsies (T) and cancer The expression of circRNF13 finds that circRNF13 expresses notable downward in Dendritic cell biopsy.

Figure 11：It is had detected in control tissue (left side) by the Dendritic cell (right side) and cancer of archive by hybridization in situ technique The expression of circRNF13 further demonstrates circRNF13 and expresses relatively low or do not express in Dendritic cell biopsy.

Figure 12：We have collected 88 Dendritic cell tissue specimens for having Clinical Follow-up data, and in situ hybridization has detected The expression of circRNF13, wherein 21 expression (Negative) that can't detect circRNF13, the existence of these patients Time is shorter compared with other patients's (although circRNF13 expressions are not high, can detect to obtain, Positive), and prognosis is more Difference.

Specific implementation mode

It further illustrates the present invention, is not intended to limit the present invention below in conjunction with specific implementation mode.

The full length sequence that circRNF13 in Tca8113 cells is determined is sequenced in embodiment 1, PCR

1. materials and methods

1.1 cell line

Tca8113 cells Tca8113 and Cal27 are purchased from Central South University's cell centre, and normal condition is cultivated.

1.2 reagents and kit

TRIZOL^TMReagent(Invitrogen)；Plastic recovery kit (OMEGA)；Reverse Transcriptase kit (Promega)；Proteinase K, DNase I, RNAsin, RNase A (GBICOL companies)；LAEnzyme (Takara).

1.3 fluorescence quantitative PCR detection circRNF13 are expressed in Tca8113 cells

Extracted total RNA, 1 μ g RNA carry out real-time fluorescence quantitative PCR after reverse transcription is at cDNA.CircRNF13 forward directions are drawn Object is 5-GTCCAGGATAGACATAGAGC-3, such as SEQ NO:Shown in 2 and reverse primer 5-GTGTAGACTTGTGTGGCTGA- 3.Such as SEQ NO:Shown in 3.

GAPDH forward primers for control are 5 '-ACCACAGTCCATGCCATCAC-3 ' such as SEQ NO:Shown in 4, and Reverse primer 5 '-TCCACCACCCTGTTGCTGTA-3 ', such as SEQ NO:Shown in 5.

Real-time fluorescence quantitative PCR reaction system

Real-time fluorescence quantitative PCR reaction step

The amplification curve and melting curve of real-time fluorescence quantitative PCR, the expression intensity root of each gene are confirmed after reaction After CT values (threshold cycle values), reference gene (GAPDH) markization, is examined and calculated using group t-test P values.

Finally, real-time fluorescence quantitative PCR is amplified the segment come and is sequenced by us, and sequence is carried out to the segment expanded Row compare, confirm we amplification be exactly circRNF13, and obtain circRNF13 cyclisation splice specific site.

1.4 reverse transcription PCRs obtain circRNF13 overall lengths

1) using Tca8113 cells Tca8113cDNA as template, by designing two pairs of primers, it is overlapped mutually nesting twice PCR amplification overall length circRNF13 sequences (sequence obtained by design of primers and PCR amplification is as shown in Figure 2).CircRNF13 overall lengths Sequence amplification primer is as follows：

It expands for the first time, sense primer：5-GCTAGAAGAAACAGACTTCGTAAA-3；Such as SEQ NO:Shown in 6；

Downstream primer：5-CTAATGAGGTCATCAGAATCAACA-3, such as SEQ NO:, shown in 7；

Second of amplification, sense primer：5-AATGTTGATTCTGATGACCT-3, such as SEQ NO:Shown in 8,

Downstream primer：5-AGATTGTGTAGACTTGTGTGG-3, such as SEQ NO:Shown in 9.

2) PCR amplification, circRNF13 full length sequences, PCR reaction conditions are as follows：

PCR reaction steps

3) sequencing analysis is carried out after PCR product glue being recycled target fragment.

2. result

It expresses in Tca8113 cells of 2.1 circRNF13 after cisplatin treated and significantly increases

After cis-platinum (P) processing, we are had detected by real-time fluorescence quantitative PCR in cell Tca8113 cells The expression of circRNF13 finds that circRNF13 expressions are significantly raised (Fig. 1, left) compared with negative control (NC)；We In order to which that confirm real-time fluorescence quantitative PCR detection is strictly circRNF13, we carry out real-time fluorescence quantitative PCR product Sequencing analysis finds that amplified fragments are strictly that the 8 exons 3 ' end of RNF13 and 2 exons 5 ' end are spliced, strictly One new circRNA molecule.

2.2 we expand sequencing and confirm the full length sequence of circRNF13

Because circRNF13 is a new circular RNA molecule, specific sequence is especially expressed in Dendritic cell Transcript sequence need further confirmation.We design two pairs of primers and by PCR successful clones nested twice The full length sequence of circRNF13, it was confirmed that circRNF13 is strictly by the RNF13 genes on the regions chromosome 3q25.1 The 2-8 exons cyclisation of (ring finger protein 13, NM_183381.2) is spliced to form (Fig. 2), and overall length is 716bp (such as SEQ NO:Shown in 1).

Embodiment 2, circRNF13 inhibit Tca8113 cells Cycle Arrest, inducing cell apoptosis

1. materials and methods

1.1 reagents and kit

Restriction enzyme Cla I and Sac II and T4DNA ligases etc. are purchased from TakaRa companies；TRIZOL^TM Reagent(Invitrogen)；Plasmid extraction kit, plastic recovery kit (OMEGA)；Reverse Transcriptase kit (Promega)； Proteinase K, DNase I, RNAsin, RNase A (GBICOL companies)；Methyl thiazoly tetrazolium assay (MTT, Sigma)；Antibiotic G418(Ameresc)；Cell cycle detection kit (Invitrogen), cell apoptosis detection kit (Invitrogene).

The Fiber differentiation of 1.2 Dendritic cell mdr cells

In cell culture medium, the cis-platinum of low dosage is added, and cis-platin concentrations are gradually increased, is trained by long-time induction It supports, is finally obtained the drug-resistant cell strain being resistant to cis-platinum.

The structure of 1.3 circRNF13 carrier for expression of eukaryon

We are inserted into upstream and downstream in pcDNA3.1 carriers (deriving from Invitrogen companies) at multiple cloning sites first Loop-forming sequences, i.e. GTGCTGGGATTACAGGTGTGAGCTACCACCCCCGGCCCACTTTTT such as SEQ NO:Shown in 10, GAAAAGAATTAGGCTCGGCACGGTAGCTCACACCTGTAATCCCAGCA such as SEQ NO:Shown in 11) it is used to help be inserted into piece Section transcription is processed as circular rna；Here it is circular rna eukaryotic expression blank expression vectors；Specific building process is as follows：

According to the fundamentum of the Forming Mechanism of circRNA and eucaryote RNA montages, design suitable for circRNA The loop-forming sequences of expression；According to the sequence information of commercial carrier pcDNA3.1, suitable multiple cloning sites are designed, to obtain The complete DNA sequence dna realized circRNA and be overexpressed：

GTGCTGGGATTACAGGTGTGAGCTACCACCCCCGGCCCACTTTTTCTTAAGCTTGGTACCGAGCTCGGATCCACATC GATTGGTGGAATTCTGCAGATATCCACCGCGGTGGCGGCCGCTCGAGTCTAGAGAAAAGAATTAGGCTCGGCACGGT AGCTCACACCTGTAATCCCAGCA, such as SEQ NO:Shown in 12；

Intermediate underscore part is multiple cloning sites, and both ends are respectively upstream and downstream loop-forming sequences；

Above-mentioned synthesis is realized that NheI restriction enzyme site sequences, the other end are added in DNA sequence dna one end that circRNA is overexpressed Addition ApaI restriction enzyme site sequences obtain pcCirc blank by being built into pcDNA3.1 carriers after NheI and ApaI digestions Plasmid (sequence such as SEQ NO:Shown in 13), sequencing confirms that plasmid is correct.

In order to build circRNF13 over-express vectors.We select Cla I and Sac II restriction enzyme sites for digestion PcCirc empty plasmids (the i.e. above-mentioned pcDNA3.1 carriers for inserting upstream and downstream loop-forming sequences built), and will Between the upstream and downstream loop-forming sequences of circRNF13 sequence insertion vectors (Fig. 3, left).

Building circRNF13 over-express vectors (i.e. carrier for expression of eukaryon), steps are as follows：

1) using Tca8113 cells Tca8113cDNA as template, TaKaRa LA are utilizedEnzyme carries out PCR amplification overall length CircRNF13 sequences.CircRNF13 full length sequence amplimers are as follows：

Sense primer：5 '-GTGATTTTACAACGAGAT-3 ' such as SEQ NO:Shown in 14；

Downstream primer：5 '-CTTTCTTGAATTTATGTA-3 ' such as SEQ NO:Shown in 15；

In upstream and downstream, 5 ' ends of primer add restriction enzyme Cla I and Sac II recognition sites and protection alkali respectively After base, primer sequence is as follows：

Upstream：5’-AGGAATCGATGTGATTTTACAACGAGAT-3 ' (underscore part is Cla I recognition sites) is such as SEQ NO:Shown in 16；

Downstream：5’-ATGCCCGCGGCTTTCTTGAATTTATGTA-3 ' (underscore part is Sac II recognition sites) is such as SEQ NO:Shown in 17；

2) PCR amplification, circRNF13 full length sequences, PCR reaction conditions are as follows：

PCR reaction steps

3) by through Cla I and Sac II double digestion rear electrophoresis, glue returns again after PCR product electrophoresis, glue recycling target fragment It receives；

4) pcCirc empty plasmids recycle target fragment through Cla I and Sac II double digestion rear electrophoresis glue；

3) and 4) 5) with T4DNA ligases connection step glue recovery product, you can obtain can be used for eukaryotic expression circRNF13 Vector plasmid；

6) by the eukaryon expression plasmid transformed competence colibacillus large intestine bar comprising circRNF13 full length sequences that 5) step obtains Bacterium, to expand plasmid.

1.4 circRNF13 tiny RNAs interference sequences (siRNA)

We for circRNF13 splice site devise specificity siRNA (siRNA, Fig. 4, a left side are shown The position of siRNA) sequence is as follows：

5-AGAAAGGUGAUUUUACAACGA-3 such as SEQ NO:Shown in 18,

Control of the simultaneous selection in human genomic sequence there is no the Scramble sequences of target spot as siRNA：

Scramble sequences are as follows：

5’-GACACGCGACUUGUACCAC-3’.Such as SEQ NO:Shown in 19,

The sequence is synthesized by Invitrogen companies.

1.5 prepare the coated nano silicon particles of poly-D-lysine

The coated nano silicon particles of poly-D-lysine are carried out with OP-10/ hexamethylenes/ammonia microemulsion self-assembling technique The synthesis of nano silicon particles (silica nanoparticle, SiNP), and using the surface energy of nano silicon particles and pass through ion Electrostatic interaction prepares the nano silicon particles of polylysine modification；The nano particle can be prepared by following methods：

1) OP-10 (nonylphenol polyoxyethylene ether), hexamethylene and ammonium hydroxide are mixed, positive silicic acid is added after being stirred at room temperature uniformly Different ester (TEOS), continue stirring to polymerization complete, be added equal-volume acetone, ultrasonic disperse, centrifugation, distilled water wash three times, from Heart collection is deposited in 80 DEG C of dryings, finely ground to obtain nano silicon particles (SiNP, particle size range 10-50nm).Wherein H₂O and OP-10 and H₂The molar ratio of O and TEOS is 2~10, ammonia concn is 1.6~28%, molar concentrations of the TEOS in hexamethylene be 0.1~ 3mol/L。

2) SiNP is resuspended in 0.6M NaCO by 0.1~10mg/ml₃In solution, supernatant is abandoned in ultrasonic disperse, centrifugation, then Sediment is resuspended in by 0.1~10mg/ml in PBS (pH 7.4), ultrasonic disperse, add polylysine (final concentration of 4~ 15nmol/mL), it mixes well, room temperature is mixed to shake；Centrifugation, abandons supernatant, and precipitation is resuspended in distilled water by 0.1~10mg/ml, is obtained To the nano silicon particles of polylysine modification.

3) by modified nano silicon particles ultrasonic disperse, 10~50ug circRNF13 mistakes are added in every milliliter of nano particle suspension Expression vector or 10-100pmol siRNA, mixing, are stored at room temperature and make it combine.

1.6 cell culture and transfection

The good Tca8113 cells Tca8113 and Cal27 of growth conditions or mdr cell are pressed 2 × 10⁵A cells/well It is inoculated in 6 orifice plates, 6 orifice plates is placed in 37 DEG C, 5%CO₂In incubator, cell growth to be cultivated to 50-70% density Start circRNF13 over-express vectors or the transfection of siRNA；Transfection process is as follows：

The poly that carrying circRNF13 eukaryon expression plasmids or siRNA that 100 μ l are prepared are added in sterile EP tube relies The nano silicon particles suspension of propylhomoserin modification, with the 100 mild mixings of μ l serum free mediums；Cell is washed with D-Hank's liquid 3 times； 800 μ l serum free mediums (antibiotic-free) will be added in said mixture, 1 hole in 6 orifice plates is added after mild mixing；It will 6 orifice plates are placed in CO₂In incubator, 37 DEG C are cultivated 6 hours, and supernatant is then abandoned, and complete medium is added and continues overnight incubation.With sky The nano silicon particles of carrier or the polylysine modification of Scramble sequences are as experiment contrast.1.7 real time fluorescent quantitative PCR detects the expression of intracellular circRNF13

After cell processing, in suitable time point collecting cell, extracted total RNA, 1 μ g RNA after reverse transcription is at cDNA, Carry out real-time fluorescence quantitative PCR.CircRNF13 forward primers are 5-GTCCAGGATAGACATAGAGC-3, such as SEQ NO:2 institutes Show and reverse primer 5-GTGTAGACTTGTGTGGCTGA-3.Such as SEQ NO:Shown in 3.

GAPDH forward primers for control are 5 '-ACCACAGTCCATGCCATCAC-3 ' such as SEQ NO:Shown in 4, and Reverse primer 5 '-TCCACCACCCTGTTGCTGTA-3 ', such as SEQ NO:Shown in 5.

Real-time fluorescence quantitative PCR reaction system

Real-time fluorescence quantitative PCR reaction step

The amplification curve and melting curve of real-time fluorescence quantitative PCR, the expression intensity root of each gene are confirmed after reaction After CT values (threshold cycle values), reference gene (GAPDH) markization, is examined and calculated using group t-test P values.

1.8 MTT cell proliferation experiments

1) digest cell obtained in the previous step, cell counted with cell counter, will transfection circRNF13 and The cell inoculation of pcDNA3.1 empty carriers is inoculated with 1000 cells per hole, as a result each 5 hole of cell inoculation takes in 96 orifice plates Its mean value.

2) 37 DEG C, 5%CO₂Incubator culture 6 hours adds 20 μ l of MTT liquid (5mg/ml) after cell is adherent per hole.After It is continuous to be incubated 4 hours, culture is terminated, culture solution is discarded.150 μ l DMSO are added per hole, vibrate 10 minutes, crystal is made to dissolve.

3) 490nm wavelength is selected, zeroing hole is concurrently set, on enzyme-linked immunosorbent assay instrument, measures each hole absorbance value simultaneously Record result.

4) it is same as above every 24 hours repetition steps, detects 6 days altogether.Using absorbance value as ordinate, interval time is horizontal seat Plotting MTT curves.

5) it tests in triplicate.Using each time point as abscissa, absorbance value is ordinate, draws cell growth curve.

1.9 flow cytometry analysis cell cycles

1) trypsin digestion cell when culture cell reaches 85% fusion, 1200rpm/min centrifuge 5min, and it is heavy to collect cell It forms sediment.

2) cell is resuspended in 1xPBS, and 1200rpm/min centrifuges 5min, collects cell.Repeat this step 2 time.

3) cell is resuspended in 1xPBS, and 70% ethyl alcohol that precooling is added fixes cell pellet overnight.

4) 1000rcf/min centrifuges 5min, collects cell precipitation.

5) PH7.4PBS washs cell 1 time, PBS is added after centrifugation, cell is resuspended, and adjust cell concentration to Ix 10⁶/ ml。

6) propidium iodide (PI) dyeing liquor (PI containing 50mg/L, 1g/L Triton X-100,100g/L RNase) is added Mixing, 4 DEG C are protected from light incubation 30min.

7) flow cytometer FACStar (U.S. company BD) is detected.Received signal is handled through Cellquest softwares, right The fluorescence intensity of detection cell is analyzed.Experiment is repeated 3 times.

1.10 flow cytometry analysis natural death of cerebral cells rates

1) it when culture cell reaches 85% fusion, digests each group cell with pancreatin and is collected in centrifuge tube, be collected simultaneously Each group supernatant suspension cell.Pay attention to gently blowing and beating cell, pancreatin is avoided excessively to digest.

2) merge each group cell respectively and be transferred in centrifuge tube, 1000rpm centrifuges 5min, abandons supernatant and collects cell, PBS After being gently resuspended, cell count.

3) it takes 5~100,000 resuspension cells, 1000rpm to centrifuge 5min, abandon supernatant, 195ul Annexin V-FITC knots is added It closes liquid and cell is gently resuspended.

4) 5ul Annexin V are added, gently mixing.It is protected from light incubation at room temperature 10min.

5) 1000rpm centrifuges 5min, abandons supernatant, 190ul Annexin V-FITC combination liquid is added, cell is gently resuspended.

6) 10ul PI dyeing liquors are added, gently mixing, ice bath are protected from light.

7) flow cytomery is carried out immediately, and Annexin V-FITC are green fluorescence, and PI is red fluorescence.

2. result

2.1 circRNF13 inhibit the growth of Tca8113 cells

After transfecting circRNF13 carrier for expression of eukaryon, we are had detected by real-time fluorescence quantitative PCR in cell The expression of circRNF13 finds that circRNF13 expressions are significantly raised (Fig. 3)；And transfect the small dry of targeting circRNF13 After disturbing RNA (siRNA), the expression of intracellular circRNF13 obviously lowers (Fig. 4)；

Compared with the cell of transfection empty carrier, it is overexpressed the life of the Tca8113 cells Tca8113 and Cal27 of circRNF13 Long speed significantly slows down, and after striking the expression of low circRNF13 using siRNA interference sequences, vitro growth rates accelerate (figure 5)。

2.2 circRNF13 inhibit the growth of Tca8113 cells by arresting cell cycle, inducing cell apoptosis.

Flow cytometry analysis shows after transfecting circRNF13 in Tca8113 cells that G2/M phase cell proportions significantly increase Add, and S phase cell proportions are reduced, and show that circRNF13 can block Tca8113 cells in the G2/M phases, make its cell division slow Speed (Fig. 6).Meanwhile apoptotic cell ratio obviously increases (Fig. 7) after transfection circRNF13 in Tca8113 cells, this is also CircRNF13 inhibits one of the reason of Tca8113 cells growth.And it strikes low circRNF13 and has then obtained opposite result.

2.3 circRNF13 express downward in Dendritic cell mdr cell

We by some months are cultivated by being stepped up cis-platin concentrations in the medium, and successfully induction obtains Tca8113 and Cal27 has detected the expression of circRNF13 in cell to the cell of cisplatin resistance, real-time quantitative PCR, sends out Existing expression of the circRNF13 in drug-resistant cell strain has significantly lowered (Fig. 8) compared with initial cell strain.

2.4 overexpression circRNF13 can reverse Tca8113 cells drug-resistant phenotype

The expression (si-circRNF13) of low circRNF13 is struck in original Tca8113 cells (NC) or in mdr cell (CR) after being overexpressed circRNF13 (OE-circRNF13) in, with the cisplatin treated cell of same concentrations, then flow cytometer Apoptosis situation is detected, the tolerance (apoptosis reduction) that the expression of low circRNF13 can increase cell to cis-platinum is struck in discovery, and The drug resistance (Fig. 9) of mdr cell can then be significantly reduced by being overexpressed circRNF13.

Embodiment 3, quantitative real-time PCR detection confirm that circRNF13 expresses downward in Dendritic cell

1. materials and methods：

Collect by 28 Dendritic cells and 28 Dendritic cell tissues, extracted total RNA, 1 μ g RNA after reverse transcription is at cDNA, into Row real-time fluorescence quantitative PCR.CircRNF13 forward primers are 5-GTCCAGGATAGACATAGAGC-3, such as SEQ NO:Shown in 2, With reverse primer 5-GTGTAGACTTGTGTGGCTGA-3.Such as SEQ NO:Shown in 3.

GAPDH forward primers for control are 5 '-ACCACAGTCCATGCCATCAC-3 ' such as SEQ NO:Shown in 4, and Reverse primer 5 '-TCCACCACCCTGTTGCTGTA-3 ', such as SEQ NO:Shown in 5.

Real-time fluorescence quantitative PCR reaction system

Real-time fluorescence quantitative PCR reaction step

The amplification curve and melting curve of real-time fluorescence quantitative PCR, the expression intensity root of each gene are confirmed after reaction After CT values (threshold cycle values), reference gene (GAPDH) markization, is examined and calculated using group t-test P values.

2. result

CircRNF13 expressed in control tissue by cancer it is higher, and in Dendritic cell tissue expression significantly reduce P<0.01 (Figure 10).

Embodiment 4, in situ hybridization detection find that low expressions of the circRNF13 in Dendritic cell is related to patient's poor prognosis

1. MATERIALS METHODS

1.1 design and synthesize hybridization probe

In order to detect the expression of circRNF13 using in-situ hybridization method, we are for circRNF13 cyclisation splicings Site (namely 2 exon of RNF13 genes and 8 exon stitching portions) devises oligonucleotide probe 1, and is used as The in situ hybridization oligonucleotide probe of positive control 3.

Oligonucleotide probe in situ hybridization detection circRNF13 expression： TCGTTGTAAAATCACCTTTCTTGAATTTAT is such as：SEQ NO:Shown in 20,

Positive control probe (detection house-keeping gene GAPDH)：

GAPDH probes 1：5 '-CCACTTTACCAGAGTTAAAAGCAGCCCTGG-3 ', such as SEQ NO:Shown in 21,

GAPDH probes 2：5 '-CAGTAGAGGCAGGGATGATGTTCTGGAGAG-3 ', such as SEQ NO:Shown in 22,

GAPDH probes 3：5 '-GTCAGAGGAGACCACCTGGTGCTCAGTGTA-3 ', such as SEQ NO:Shown in 23.

Each gene specific oligonucleotides probe sequence of above-mentioned design is synthesized using chemical synthesis process.

1.2 oligonucleotide probe labelling kits and in situ hybridization detection reagent

Digoxin oligonucleotides tailing reagent (Dig Oligonucleitide Tailing Kit 2^ndGeneration, Roche companies), anti-digoxin-horseradish peroxidase complex detection kit (Anti-Digoxigenin-POD, Fab Fragments, Roche company), enhance the TSA signal amplifying systems (TSA of detection of expression signal in situ^TM Biotin System, NEL700 kit, PerkinElmer companies), DAB staining kits (Beijing Zhong Shan companies), 20x sodium citrates Buffer solution (saline sodium citrate, SSC), dextran sulfate (Dextran sulphate), deionized formamide (Deionized Formamide), polyadenylic acid (polyadenylic acid, Poly A), poly deoxyadenylic acid (polydeoxyadenylic acid, Poly dA) is denaturalized frog essence DNA (the denatured and sheared of shearing Salmon sperm DNA, ssDNA), yeast transfer RNA (yeast t-RNA, tRNA), dithiothreitol (DTT) (DTT), 50x Deng Han Family name's buffer solution (Denhardts ' s solution), phosphate buffer (PBS buffer), pepsin K, bovine serum albumin(BSA) (BSA), triethanolamine (TEA), TNB Buffer (0.1M Tris-HCl, pH7.5,0.15M NaCL, 0.5%Blocking Reagent), TNT Buffer (0.1M Tris-HCl, pH7.5,0.15M NaCL, 0.05%Tween 20), acetic anhydride, resistance Disconnected reagent (Blocking reagent agent, Roche companies).

1.3 other main agents and material

Absolute ethyl alcohol, 90% alcohol, 70% alcohol, 50% alcohol, turpentine oil, distilled water, PBS buffer solution (pH7.2~ 7.4, NaCl 137mmol/L, KCl 2.7mmol/L, Na₂HPO₄4.3mmol/L, KH₂PO₄1.4mmol/L)；3% methanol- Hydrogen peroxide solution (80% methanol and the configuration of 30% hydrogen peroxide)；0.01mol/L citrate buffers (citrate buffer, CB, pH6.0 ± 0.1,9ml 0.1M citric acid solutions and 41ml 0.1M sodium citrate solutions are added interim in 450ml distilled water With postponing correction work liquid pH value again)；0.1% trypsase；Haematoxylin；1% hydrochloride alcohol (1ml concentrated hydrochloric acid+99ml70% wine Essence configuration)；Mounting glue (PTS Cure Mount II)；Special coverslip (480 × 240mm²) customize in Zhengzhou Glassware Factory. Leica low melting points (58 DEG C) paraffin, domestic beeswax, absolute alcohol, dimethylbenzene, 10% neutrality paraformaldehyde (0.01mol/L, PH7.4, DEPC distilled water and PBS buffer solution are prepared), haematoxylin, Yihong, neutral mounting natural gum, coverslip, glass slide.

1.4 label probe

Oligonucleotide probe label is carried out using 3-tailing DIG Olignucleutide Kit, reaction system is such as Under.

100pmol oligonucleotide+ddH₂O=9 μ l (control:control oligonucleutide 5μ l+ddH₂O4μl)

Mixing slightly centrifuges.37 DEG C of water-bath 30min add 2 μ l EDTA (0.2M, PH 8.0) stopped reactions.

It is purified after 1.5 oligonucleotide probes label

In order to increase the purity of label probe, marked probe need to be purified, concrete operations are as follows：

1) 100% cold ethyl alcohol (- 20 DEG C) of+2.5 μ l 4M LiCL+75 μ l of probe reaction mixture (22 μ l)

2) -70 DEG C of precipitations 60min, or-20 DEG C of 2h.

3) 13.000 × g, 4 DEG C of centrifugation 15min.

4) supernatant is abandoned, is washed with 70% ice-cold (V/V) ethyl alcohol of 50 μ l.

5) 4 DEG C of 13.000xg centrifuge 5min.

6) supernatant, 4 DEG C of dryings of vacuum are abandoned.

7) with the molten probe of aseptic double-distilled water weight.

1.6 in situ hybridizations detection achieves the expression of circRNF13 in paraffin section

Paraffin section hybridizes pre-treatment

1) paraffin section of 4 DEG C of preservations is placed in 58 DEG C of roasting piece 30min, melted surface paraffin.

2) dimethylbenzene dewaxes 3 × 5min successively.

3) step ethanol wash, 100% 1 × 5min of the alcohol of 2 × 2min of alcohol → 95% alcohol of 1 × 5min → 70% → 50% 1 × 5min of alcohol → 2 × 3min of DEPC water washings → DEPC-PBS washs 2 × 5min.

4) 300 μ l pepsins K (10 μ g/ml) are added dropwise on slice, 37 DEG C digest 20min.

5) it is sliced and washs 1min, stopped reaction into PBS (0.1M PBS+2mg/ml glutamic acid).

6) it is sliced into 0.2N HCL, reacts 20-30min in 37 DEG C, increase the permeability of tissue.

7) slice fixes 10min, room temperature afterwards with 4% paraformaldehyde (0.1M PBS dissolvings).

8) in order to increase tissue positive intensity for hybridization, acetyl processing is carried out to slice.It is sliced into 0.25% acetic anhydride Buffer I (0.1M triethanolamines), room temperature 10min.

9) 1M PBS wash 2 × 5min.

Prehybridization and hybridization

Prehybridization：The prehybridization solution of -20 DEG C of preservations is first placed in 37 DEG C of incubation 60min, and the dosage of prehybridization solution is 50 μ l, Parafilm is carried out lid and is sliced, prehybridization 2 hours in 37 DEG C of wet box.(prehybridization solution composition includes：2XSSC, 10%Dextran Sulphate, 1X Denhardt ' s solution, 50mM Phosphate Buffer (PH 7.0), 50mM DTT, 250 μ l, 100 μ g/ml poly A, 5 μ g/ml poly dA, 250 μ g/ml yeast t-RNA, 500 μ g/ml ssDNA, 47% Deionized formamide)。

1) parafilm is removed, prehybridization solution is got rid of, slice is placed in 5min in 2 × SSC.

2) hybridization reaction：37 DEG C of hybridized overnights (18-20h).Each slice is added 250 μ l hybridization solutions and is carried out with parafilm Lid.Corresponding probe is added in prehybridization solution just becomes hybridization solution.Hybridization solution is prepared in prehybridization, is placed 37 DEG C of incubations, is made Probe is completely dissolved in hybridization solution, this experiment is mixed with a plurality of oligonucleotide probe, is matched by each probe 500ng/ml concentration Probe hybridization solution is made.Digoxin tailing labelling kit label probe concentration calculation basis：The concentration of each probe by its with Colour developing is compared and the label reaction theory spy of the naked probe of 30 bases of 100pmol when detection reaction when the positive quantifies probe Needle yield is that two kinds of standards of 900ng carry out the concentration that COMPREHENSIVE CALCULATING goes out label probe.

3) post-hybridization washing, slice immerse 2 × SSC, 10min, throw off parafilm.It is washed successively in shake on shaking table, 2 × SSC (0.5%SDS), 2 × 15min → 0.25 × SSC (0.5%SDS), 2 × 15min.

Color developing detection is reacted after hybridization

1) Anti-Digoxigenin-POD detection digoxigenin-probes and mRNA combination compounds are used；TSA amplification systems Enhance the positive signal of in situ hybridization reaction solution reaction, DAB colour developings.

2) slice is gone in TNT buffer solutions, 3 × 5min.

3) TNB is added dropwise and blocks buffer solution, 300 μ l/TMAs, room temperature, 30min.

4) extra blocking agent is sucked, 1:100 diluted Anti-Digoxigenin-POD (TBS+0.1%Triton X- 100+1% blocking agents), room temperature 4 hours.

5) TNT Buffer (0.1M Tris-CL, pH7.5,0.15M NaCL, 0.05%Tween 20) are washed, 3x5min。

6) signal amplification reagent Biotinyl Tyamid, 300 μ l/TMAs, (Biotinyl Tyramid are added dropwise on slice Store liquid：Biotinyl Tyramid are dissolved in 0.2ml DMSO, Biotinyl Tyramid working solutions：1 × dilution, 1:50 Dilute Biotinyl Tyramid and store liquid), room temperature 10 minutes.

7) TNT is washed, 3 × 5min.

8) SA-HRP (strepto- avidin-horseradish peroxidase), 300 μ l/TMAs, room temperature 30min are added dropwise in slice.

9) TNT is washed, 3 × 5min.

10) distilled water washing, 1 × 1min.

11) DAB develops the color, and chromogenic reaction is controlled under microscope.

12) haematoxylin is redyed,

13) alcohol step is dehydrated, chip drying.

14) mounting glue, the coverslip cover plate of dimension, crosslinking slice 1min under ultraviolet lamp is added dropwise.

1.7 results judge and standard

Application Optics microscope is observed under low power and high power lens respectively, looks first at the positive expression of target RNA The signal positioning intracellular in object observing：Positioned at nucleus, cytoplasm or cell membrane.

It is carried out respectively with two kinds of standards of the intensity of the detection rna expression position positive signal and the cell number of positive expression again Comprehensive score, criterion are：(1) judge according to positive cell dyeing intensity：A. cell dye-free remembers 0 point；B. cell is dyed Light brown is weakly positive, remembers 1 point；C. cell dyes brown and dyes dark-brown without background coloration or cell and have the light brown back of the body Scape is moderate positive, remembers 2 points；D. cell dyes dark-brown and is strong positive without background coloration, remembers 3 points.(2) according to positive cell Express number score：A. no positive cell expression, remembers 0 point；B. positive expression cell number≤25% remembers 1 point；C.25% ＜ is positive thin Born of the same parents' number ＜ 50% remembers 2 points；D. positive expression cell number >=50% remembers 3 points.

In order to reduce the subjective factor of appraisal result as possible, one of above-mentioned standard is pressed respectively respectively by two pathology experts Judged and scored, then the two is scored and is multiplied, result is：1. 0 point of person is finally calculated as 0 point, it is believed that feminine gender expression；2. 1 point It is finally calculated as 1 point with 2 points of persons, it is believed that weakly positive is expressed；3. 3 points and 4 points of persons are finally calculated as 2 points, it is believed that moderate positive is expressed；④ 6, which assign to 9 points of persons, is finally calculated as 3 points, it is believed that strong positive is expressed.

1.8 analyses and statistical software

Statistical analysis is carried out to experimental result using SPSS13.0 statistical softwares, compares use χ two-by-two²Test or Fisher Exact test, correlation analysis use Spearmen correlation methods；P ＜ 0.05 are that difference is statistically significant. Survivorship curve analysis uses Kaplan-Meier method and log-rank test；Multi-variables analysis uses Cox ' s proportional hazards model；P ＜ 0.05 are that difference is statistically significant.

2 results

Expression of 2.1 circRNF13 in Dendritic cell raising more notable than expression in normal control tissue

CircRNF13 is not expressed in Dendritic cell tissue or expression is relatively low, and the normal control by Dendritic cell cancer There is expression (Figure 11) in tissue, there is apparent significant difference between the two.

Dendritic cell patient's prognosis of 2.2 circRNF13 low expressions is worse

Effect of follow-up visit by telephone has been carried out to 88 Dendritic cell patients, inquired in detail they start time, treatment, whether there is or not Recurrence, whether there is or not suffering from other diseases, recurrence and death time etc. again, and register life span and state, and to Dendritic cell tissue The survival analysis that the expression of middle circRNF13 and the life span of patient and state carry out finds not express in Dendritic cell tissue The patient of circRNF13 is significantly shorter than circRNF13 the mean survival times and expresses higher patient (Figure 12).Explanation CircRNF13 is one and the relevant molecular labeling of Dendritic cell prognosis, and circRNA expression is low or does not express, patient's poor prognosis.

Sequence table

<110>Central South University

<120>The application process of circular rna circRNF13

<160> 23

<170> SIPOSequenceListing 1.0

<210> 1

<211> 716

<212> RNA

<213>Homo sapiens (Homo sapiens)

<400> 1

gugauuuuac aacgagaugc ugcucuccau agggaugcuc augcugucag ccacacaagu 60

cuacaccauc uugacugucc agcucuuugc auucuuaaac cuacugccug uagaagcaga 120

cauuuuagca uauaacuuug aaaaugcauc ucagacauuu gaugaccucc cugcaagauu 180

ugguuauaga cuuccagcug aagguuuaaa ggguuuuuug auuaacucaa aaccagagaa 240

ugccugugaa cccauagugc cuccaccagu aaaagacaau ucaucuggca cuuucaucgu 300

guuaauuaga agacuugauu guaauuuuga uauaaagguu uuaaaugcac agagagcagg 360

auacaaggca gccauaguuc acaauguuga uucugaugac cucauuagca ugggauccaa 420

cgacauugag guacuaaaga aaauugacau uccaucuguc uuuauuggug aaucaucagc 480

uaauucucug aaagaugaau ucacauauga aaaagggggc caccuuaucu uaguuccaga 540

auuuagucuu ccuuuggaau acuaccuaau ucccuuccuu aucauagugg gcaucugucu 600

caucuugaua gucauuuuca ugaucacaaa auuuguccag gauagacaua gagcuagaag 660

aaacagacuu cguaaagauc aacuuaagaa acuuccugua cauaaauuca agaaag 716

<210> 2

<211> 20

<212> DNA

<213>Unknown (Unknown)

<400> 2

gtccaggata gacatagagc 20

<210> 3

<211> 20

<212> DNA

<213>Unknown (Unknown)

<400> 3

gtgtagactt gtgtggctga 20

<210> 4

<211> 20

<212> DNA

<213>Unknown (Unknown)

<400> 4

accacagtcc atgccatcac 20

<210> 5

<211> 20

<212> DNA

<213>Unknown (Unknown)

<400> 5

tccaccaccc tgttgctgta 20

<210> 6

<211> 24

<212> DNA

<213>Unknown (Unknown)

<400> 6

gctagaagaa acagacttcg taaa 24

<210> 8

<211> 24

<212> DNA

<213>Unknown (Unknown)

<400> 8

ctaatgaggt catcagaatc aaca 24

<210> 8

<211> 20

<212> DNA

<213>Unknown (Unknown)

<400> 8

aatgttgatt ctgatgacct 20

<210> 9

<211> 21

<212> DNA

<213>Unknown (Unknown)

<400> 9

agattgtgta gacttgtgtg g 21

<210> 10

<211> 45

<212> DNA

<213>Unknown (Unknown)

<400> 10

gtgctgggat tacaggtgtg agctaccacc cccggcccac ttttt 45

<210> 11

<211> 47

<212> DNA

<213>Unknown (Unknown)

<400> 11

gaaaagaatt aggctcggca cggtagctca cacctgtaat cccagca 47

<210> 12

<211> 177

<212> DNA

<213>Unknown (Unknown)

<400> 12

gtgctgggat tacaggtgtg agctaccacc cccggcccac tttttcttaa gcttggtacc 60

gagctcggat ccacatcgat tggtggaatt ctgcagatat ccaccgcggt ggcggccgct 120

cgagtctaga gaaaagaatt aggctcggca cggtagctca cacctgtaat cccagca 177

<210> 13

<211> 5515

<212> DNA

<213>Unknown (Unknown)

<400> 13

gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgctctgatg 60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420

attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt 480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctagc 900

gtgctgggat tacaggtgtg agctaccacc cccggcccac ttttttttaa acttaagctt 960

ggtaccgagc tcggatccac atcgattggt ggaattctgc agatatccac cgcggtggcg 1020

gccgctcgag tctagagaaa agaattaggc tcggcacggt agctcacacc tgtaatccca 1080

gcagggcccg tttaaacccg ctgatcagcc tcgactgtgc cttctagttg ccagccatct 1140

gttgtttgcc cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt 1200

tcctaataaa atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg 1260

ggtggggtgg ggcaggacag caagggggag gattgggaag acaatagcag gcatgctggg 1320

gatgcggtgg gctctatggc ttctgaggcg gaaagaacca gctggggctc tagggggtat 1380

ccccacgcgc cctgtagcgg cgcattaagc gcggcgggtg tggtggttac gcgcagcgtg 1440

accgctacac ttgccagcgc cctagcgccc gctcctttcg ctttcttccc ttcctttctc 1500

gccacgttcg ccggctttcc ccgtcaagct ctaaatcggg ggctcccttt agggttccga 1560

tttagtgctt tacggcacct cgaccccaaa aaacttgatt agggtgatgg ttcacgtagt 1620

gggccatcgc cctgatagac ggtttttcgc cctttgacgt tggagtccac gttctttaat 1680

agtggactct tgttccaaac tggaacaaca ctcaacccta tctcggtcta ttcttttgat 1740

ttataaggga ttttgccgat ttcggcctat tggttaaaaa atgagctgat ttaacaaaaa 1800

tttaacgcga attaattctg tggaatgtgt gtcagttagg gtgtggaaag tccccaggct 1860

ccccagcagg cagaagtatg caaagcatgc atctcaatta gtcagcaacc aggtgtggaa 1920

agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat tagtcagcaa 1980

ccatagtccc gcccctaact ccgcccatcc cgcccctaac tccgcccagt tccgcccatt 2040

ctccgcccca tggctgacta atttttttta tttatgcaga ggccgaggcc gcctctgcct 2100

ctgagctatt ccagaagtag tgaggaggct tttttggagg cctaggcttt tgcaaaaagc 2160

tcccgggagc ttgtatatcc attttcggat ctgatcaaga gacaggatga ggatcgtttc 2220

gcatgattga acaagatgga ttgcacgcag gttctccggc cgcttgggtg gagaggctat 2280

tcggctatga ctgggcacaa cagacaatcg gctgctctga tgccgccgtg ttccggctgt 2340

cagcgcaggg gcgcccggtt ctttttgtca agaccgacct gtccggtgcc ctgaatgaac 2400

tgcaggacga ggcagcgcgg ctatcgtggc tggccacgac gggcgttcct tgcgcagctg 2460

tgctcgacgt tgtcactgaa gcgggaaggg actggctgct attgggcgaa gtgccggggc 2520

aggatctcct gtcatctcac cttgctcctg ccgagaaagt atccatcatg gctgatgcaa 2580

tgcggcggct gcatacgctt gatccggcta cctgcccatt cgaccaccaa gcgaaacatc 2640

gcatcgagcg agcacgtact cggatggaag ccggtcttgt cgatcaggat gatctggacg 2700

aagagcatca ggggctcgcg ccagccgaac tgttcgccag gctcaaggcg cgcatgcccg 2760

acggcgagga tctcgtcgtg acccatggcg atgcctgctt gccgaatatc atggtggaaa 2820

atggccgctt ttctggattc atcgactgtg gccggctggg tgtggcggac cgctatcagg 2880

acatagcgtt ggctacccgt gatattgctg aagagcttgg cggcgaatgg gctgaccgct 2940

tcctcgtgct ttacggtatc gccgctcccg attcgcagcg catcgccttc tatcgccttc 3000

ttgacgagtt cttctgagcg ggactctggg gttcgaaatg accgaccaag cgacgcccaa 3060

cctgccatca cgagatttcg attccaccgc cgccttctat gaaaggttgg gcttcggaat 3120

cgttttccgg gacgccggct ggatgatcct ccagcgcggg gatctcatgc tggagttctt 3180

cgcccacccc aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac 3240

aaatttcaca aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat 3300

caatgtatct tatcatgtct gtataccgtc gacctctagc tagagcttgg cgtaatcatg 3360

gtcatagctg tttcctgtgt gaaattgtta tccgctcaca attccacaca acatacgagc 3420

cggaagcata aagtgtaaag cctggggtgc ctaatgagtg agctaactca cattaattgc 3480

gttgcgctca ctgcccgctt tccagtcggg aaacctgtcg tgccagctgc attaatgaat 3540

cggccaacgc gcggggagag gcggtttgcg tattgggcgc tcttccgctt cctcgctcac 3600

tgactcgctg cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt 3660

aatacggtta tccacagaat caggggataa cgcaggaaag aacatgtgag caaaaggcca 3720

gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc 3780

ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact 3840

ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct 3900

gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcatag 3960

ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca 4020

cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa 4080

cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc 4140

gaggtatgta ggcggtgcta cagagttctt gaagtggtgg cctaactacg gctacactag 4200

aagaacagta tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg 4260

tagctcttga tccggcaaac aaaccaccgc tggtagcggt ttttttgttt gcaagcagca 4320

gattacgcgc agaaaaaaag gatctcaaga agatcctttg atcttttcta cggggtctga 4380

cgctcagtgg aacgaaaact cacgttaagg gattttggtc atgagattat caaaaaggat 4440

cttcacctag atccttttaa attaaaaatg aagttttaaa tcaatctaaa gtatatatga 4500

gtaaacttgg tctgacagtt accaatgctt aatcagtgag gcacctatct cagcgatctg 4560

tctatttcgt tcatccatag ttgcctgact ccccgtcgtg tagataacta cgatacggga 4620

gggcttacca tctggcccca gtgctgcaat gataccgcga gacccacgct caccggctcc 4680

agatttatca gcaataaacc agccagccgg aagggccgag cgcagaagtg gtcctgcaac 4740

tttatccgcc tccatccagt ctattaattg ttgccgggaa gctagagtaa gtagttcgcc 4800

agttaatagt ttgcgcaacg ttgttgccat tgctacaggc atcgtggtgt cacgctcgtc 4860

gtttggtatg gcttcattca gctccggttc ccaacgatca aggcgagtta catgatcccc 4920

catgttgtgc aaaaaagcgg ttagctcctt cggtcctccg atcgttgtca gaagtaagtt 4980

ggccgcagtg ttatcactca tggttatggc agcactgcat aattctctta ctgtcatgcc 5040

atccgtaaga tgcttttctg tgactggtga gtactcaacc aagtcattct gagaatagtg 5100

tatgcggcga ccgagttgct cttgcccggc gtcaatacgg gataataccg cgccacatag 5160

cagaacttta aaagtgctca tcattggaaa acgttcttcg gggcgaaaac tctcaaggat 5220

cttaccgctg ttgagatcca gttcgatgta acccactcgt gcacccaact gatcttcagc 5280

atcttttact ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa 5340

aaagggaata agggcgacac ggaaatgttg aatactcata ctcttccttt ttcaatatta 5400

ttgaagcatt tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa 5460

aaataaacaa ataggggttc cgcgcacatt tccccgaaaa gtgccacctg acgtc 5515

<210> 14

<211> 18

<212> DNA

<213>Unknown (Unknown)

<400> 14

gtgattttac aacgagat 18

<210> 15

<211> 18

<212> DNA

<213>Unknown (Unknown)

<400> 15

ctttcttgaa tttatgta 18

<210> 16

<211> 28

<212> DNA

<213>Unknown (Unknown)

<400> 16

aggaatcgat gtgattttac aacgagat 28

<210> 17

<211> 28

<212> DNA

<213>Unknown (Unknown)

<400> 17

atgcccgcgg ctttcttgaa tttatgta 28

<210> 18

<211> 21

<212> RNA

<213>Unknown (Unknown)

<400> 18

agaaagguga uuuuacaacg a 21

<210> 19

<211> 19

<212> RNA

<213>Unknown (Unknown)

<400> 19

gacacgcgac uuguaccac 19

<210> 20

<211> 30

<212> DNA

<213>Unknown (Unknown)

<400> 20

tcgttgtaaa atcacctttc ttgaatttat 30

<210> 21

<211> 30

<212> DNA

<213>Unknown (Unknown)

<400> 21

ccactttacc agagttaaaa gcagccctgg 30

<210> 22

<211> 30

<212> DNA

<213>Unknown (Unknown)

<400> 22

cagtagaggc agggatgatg ttctggagag 30

<210> 23

<211> 30

<212> DNA

<213>Unknown (Unknown)

<400> 23

gtcagaggag accacctggt gctcagtgta 30

Claims (4)

1. the application process of circular rna circRNF13, which is characterized in that the reagent for promoting circRNF13 expression is preparing reduction Tca8113 cells are to the application on cis-platinum class drug resistance preparation, the sequence such as SEQ of the circular rna circRNF13 NO:Shown in 1.

2. application according to claim 1, which is characterized in that the examination for promoting circular rna circRNF13 expression Agent is circRNF13 over-express vectors.

3. application according to claim 1, which is characterized in that the building process of circRNF13 over-express vectors is as follows：

(1) it according to the fundamentum of the Forming Mechanism of circRNA and eucaryote RNA montages, designs suitable for circRNA tables The loop-forming sequences reached；According to the sequence information of commercial carrier pcDNA3.1, multiple cloning sites are designed, to obtain complete reality The DNA sequence dna that existing circRNA is overexpressed is as follows：

GTGCTGGGATTACAGGTGTGAGCTACCACCCCCGGCCCACTTTTTCTTAAGCTTGGTACCGAGCTCGGATCCA CATCGATTGGTGGAATTCTGCAGATATCCACCGCGGTGGCGGCCGCTCGAGTCTAGAGAAAAGAATTAGGCTCGGCA CGGTAGCTCACACCTGTAATCCCAGCA, intermediate underscore part are multiple cloning sites, and both ends are respectively upstream and downstream cyclization Sequence；

(2) above-mentioned synthesis is realized that NheI restriction enzyme site sequences, the other end are added in DNA sequence dna one end that circRNA is overexpressed Addition ApaI restriction enzyme site sequences obtain pcCirc blank by being built into pcDNA3.1 carriers after NheI and ApaI digestions Plasmid, sequencing confirm that plasmid is correct, sequence such as SEQ NO:Shown in 13；

(3) selection Cla I and Sac II restriction enzyme sites are used for digestion pcCirc empty plasmids, and circRNF13 sequences are inserted into Between the upstream and downstream loop-forming sequences of carrier.

4. application according to claim 3, which is characterized in that the detailed process of step (3) is as follows：

1) using Tca8113 cells Tca8113cDNA as template, TaKaRa LA are utilizedEnzyme carries out PCR amplification overall length CircRNF13 sequences；CircRNF13 full length sequence amplimers are as follows：

Sense primer：5’-GTGATTTTACAACGAGAT-3’；

Downstream primer：5’-CTTTCTTGAATTTATGTA-3’；

After 5 ' ends of upstream and downstream primer add restriction enzyme Cla I and Sac II recognition sites and protection base respectively, Primer sequence is as follows：

Sense primer：5’-AGGAATCGAT GTGATTTTACAACGAGAT-3 ', underscore part are Cla I recognition sites；

Downstream primer：5’-ATGCCCGCGG CTTTCTTGAATTTATGTA-3 ', underscore part are Sac II recognition sites；

2) PCR amplification, circRNF13 full length sequences, PCR reaction conditions are as follows：

PCR reaction steps

5 return to the 2nd step, carry out 39 secondary response cycles altogether；

3) by through Cla I and Sac II double digestion rear electrophoresis, glue recycles again after PCR product electrophoresis, glue recycling target fragment；

4) pcCirc empty plasmids recycle target fragment through Cla I and Sac II double digestion rear electrophoresis glue；

5) with the connection of T4DNA ligases 3) and 4) step glue recovery product to get to the vector plasmid for being overexpressed circRNF13；

6) by the eukaryon expression plasmid transformed competence colibacillus Escherichia coli comprising circRNF13 full length sequences that 5) step obtains, with Expand plasmid.